Abivax S.A. Form 6-K Summary: Interim Results for Period Ended June 30, 2026
Business Context and Reporting Period
This Form 6-K reports the unaudited interim condensed consolidated financial results for Abivax S.A. for the three and six months ended June 30, 2026. Abivax is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory diseases. The lead drug candidate, obefazimod, is in Phase 3 trials for Ulcerative Colitis (UC) and Phase 2b for Crohn's Disease (CD). The filing incorporates a press release dated September 21, 2026.
Key Financial Metrics
| Metric (€ millions) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Operating Income | 2.5 | 2.1 |
| Research & Development Expenses | (107.9) | (77.9) |
| General & Administrative Expenses | (30.4) | (16.3) |
| Operating Loss | (140.3) | (93.7) |
| Net Loss | (165.9) | (100.8) |
| Cash and Cash Equivalents (End of Period) | 388.0 | 60.9 |
| Shareholders' Equity | 366.3 | 455.2 |
Note: All figures are in millions of euros unless otherwise stated. The company reported no revenue from product sales; operating income consists of research tax credits and depositary fees.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by 65% to €165.9 million for the six months ended June 30, 2026, compared to €100.8 million in the prior year period. This was driven by a 50% increase in operating loss and a 343% increase in financial loss.
- Financial Loss Driver: The financial loss of €31.4 million (vs. €7.1 million prior year) was primarily due to a €43.2 million loss on the derecognition of royalty certificates following their repurchase in May 2026.
- Expense Growth: R&D expenses rose 38% to €107.9 million, driven by share-based compensation (€23.7 million impact) and progression of clinical trials. G&A expenses rose 86% to €30.4 million, largely due to personnel costs and share-based compensation.
- Liquidity Position: Cash and cash equivalents increased significantly to €388.0 million as of June 30, 2026, compared to €60.9 million in the prior year, reflecting a major capital raise.
Guidance, Outlook, and Material Events
- Capital Raise (Subsequent Event): On July 6, 2026, Abivax completed a public offering of 7.36 million ADSs at $125.00 per ADS, raising net proceeds of approximately €767.1 million. Management expects this, combined with existing cash, to fund operations for at least 12 months.
- Royalty Certificate Repurchase: In May 2026, the company repurchased all outstanding royalty certificates for $90 million (€76.5 million), settling half in cash and half via equity issuance. This eliminated future royalty obligations but triggered the €43.2 million loss noted above.
- Clinical Progress:
- Ulcerative Colitis: Positive topline results announced for Part 2 of the Phase 3 ABTECT maintenance trial (June 29, 2026). The company remains on track to submit a New Drug Application (NDA) to the FDA in Q4 2026.
- Crohn's Disease: The Phase 2b ENHANCE-CD trial is ongoing, with 12-week induction topline data expected in mid-2027.
- Commercial Build-out: Significant hiring in commercial leadership (July 2026) to prepare for potential U.S. launch of obefazimod.
- Risks: The company remains pre-revenue and expects to incur significant losses until commercialization. Success depends on regulatory approval, clinical trial outcomes, and ability to secure additional financing if needed.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the €767.1 million raised in July 2026 against the projected burn rate for the NDA submission and commercial launch.
- Royalty Repurchase Impact: Confirm the non-cash nature of the €43.2 million loss and the elimination of future royalty liabilities (2% of net sales).
- Share-Based Compensation: Review the €54.0 million total share-based compensation expense for the six months ended June 30, 2026, and its impact on future dilution.
- NDA Timeline: Monitor the Q4 2026 FDA submission timeline for obefazimod in Ulcerative Colitis following the positive Phase 3 maintenance data.
- Debt Status: Confirm the full repayment of Kreos/Claret and Heights convertible notes in late 2025, leaving only minimal lease liabilities.